Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04752696 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Onvansertib
DRUG: Nanoliposomal irinotecan
DRUG: Leucovorin
DRUG: Fluorouracil

Sponsor

Cardiff Oncology